REG - Sareum Holdings PLC - Results of AGM

Sareum HoldingsAnnouncement

Tue 16:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251209:nRSI8911Ka&default-theme=true

RNS Number : 8911K  Sareum Holdings PLC  09 December 2025

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

Results of AGM

Cambridge, UK, 9 December 2025 - Sareum Holdings plc (AIM: SAR), a
clinical-stage biotechnology company developing next-generation kinase
inhibitors for autoimmune disease and cancer, held its Annual General Meeting
("AGM") today and all resolutions were duly passed. Voting was conducted by a
show of hands and inclusive of votes received by the Company by way of proxy.

 

Details of the voting results are shown in the table below:

 

 Ordinary Resolutions                                                    Votes For   %     Votes Against  %     Votes Total  % of ISC Voted  Votes Withheld
 1. Receive the financial statements for the year                        12,053,451  97.7  283,614        2.3   12,809,354   9.3             472,289
 2. Receive and approve the Directors' Renumeration Report for the year  11,035,739  87.7  1,544,196      12.3  12,809,354   9.3             229,419
 3. Re-elect Mr John Reader as Director of the Company                   11,343,737  91.9  1,000,383      8.1   12,809,354   9.3             465,234
 4. Re-appoint Moore Kinston Smith LLP as auditor                        12,356,748  97.4  325,897        2.6   12,809,354   9.3             126,709
 5. Authorise the audit committee to determine auditor renumeration      11,741,351  92.3  977,756        7.7   12,809,084   9.3             89,977
 6. Directors' authority to allot new shares                             11,305,713  89.4  1,333,162      10.6  12,809,354   9.3             170,479
 Special Resolution
 7. Authority to disapply pre-emption rights                             11,179,080  89.5  1,312,944      10.5  12,809,354   9.3             317,330
 8. Authority to hold general meetings                                   11,955,500  96.8  391,565        3.2   12,809,354   9.3             462,289

 

The full text of each of the resolutions is set out in the Notice of AGM,
available in the Investors section of the Company's website
(www.sareum.com/investors (http://www.sareum.com/investors/document-centre/) )

 

For further information, please contact:

 Sareum Holdings plc                              01223 497700

 Stephen Parker, Executive Chaiman                ir@sareum.co.uk

 Strand Hanson Limited (Nominated Adviser)        020 7409 3494

 James Dance / James Bellman

 Singer Capital Markets (Joint Corporate Broker)  020 7496 3000

 Phil Davies

 Oberon Capital (Joint Corporate Broker)          020 3179 5300

 Mike Seabrook / Nick Lovering

 ICR Healthcare (Financial PR)                    020 3709 5700

 Jessica Hodgson / Davide Salvi

About Sareum

Sareum (AIM: SAR) is a biotechnology company developing next generation kinase
inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases, with a planned
initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for certain haematological cancers and has recently initiated a
preclinical programme to develop TYK2/JAK1 inhibitors for neuroinflammatory
diseases such as multiple sclerosis and Parkinson's disease

The Company has recently acquired the license for SRA737, a clinical-stage
Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA
damage repair mechanisms.

Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(http://www.sareum.com)

- Ends -

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGFSDFMUEISEEE



            Copyright 2019 Regulatory News Service, all rights reserved